BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Abstract Hepatocellular carcinoma (HCC) represents a global health challenge with limited therapeutic options. Anti-angiogenic immune checkpoint inhibitor-based combination therapy has been introduced for progressed HCC, but improves survival only in a subset of HCC patients. Tyrosine-kinase inhibit...

Full description

Bibliographic Details
Main Authors: Stephanie Busche, Katharina John, Franziska Wandrer, Florian W. R. Vondran, Ulrich Lehmann, Heiner Wedemeyer, Frank Essmann, Klaus Schulze-Osthoff, Heike Bantel
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-04020-z

Internet

https://doi.org/10.1038/s41419-021-04020-z

Similar Items